Cargando…
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the most severe cases and when left untreated, leads to death within the first two years of life. Recent therapeutic advances have given hope to families and patients by compensating for the deficiency in survival...
Autores principales: | Chaytow, Helena, Faller, Kiterie M.E., Huang, Yu-Ting, Gillingwater, Thomas H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324491/ https://www.ncbi.nlm.nih.gov/pubmed/34337562 http://dx.doi.org/10.1016/j.xcrm.2021.100346 |
Ejemplares similares
-
Revisiting the role of mitochondria in spinal muscular atrophy
por: James, Rachel, et al.
Publicado: (2021) -
Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy
por: Motyl, Anna A L, et al.
Publicado: (2020) -
The role of survival motor neuron protein (SMN) in protein homeostasis
por: Chaytow, Helena, et al.
Publicado: (2018) -
Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017) -
Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy
por: Opris¸oreanu, Ana-Maria, et al.
Publicado: (2021)